Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Cellular & Gene Therapy Products

Cellular & Gene Therapy Products

                        Approved Cellular and Gene Therapy Products Home
          Vaccines, Blood & Biologics
          Cellular & Gene Therapy Products
          Framework for the Regulation of Regenerative Medicine ProductsCellular & Gene Therapy Products Framework for the Regulation of Regenerative Medicine Products
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe U.S. Food and Drug Administration has published four final guidance documents that are part of a comprehensive policy framework to address how the agency plans to support and expedite the development of regenerative medicine products, including human cells, tissues, and cellular and tissue-based products (HCT/Ps).  These guidance documents build upon FDA’s risk-based, flexible regulatory framework, and underscore the agency’s commitment to help bring new and innovative treatment options to patients.

The first two final guidance documents are:

Regulatory Considerations for Human Cell, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use
	Same Surgical Procedure Exception: Questions and Answers Regarding the Scope of the ExceptionThe final guidance on minimal manipulation and homologous use are intended to provide clarity in the determination of whether HCT/Ps are subject to FDA’s premarket review requirements.  The final guidance on the same surgical procedure exception is intended to provide clarity as to whether an establishment may qualify for an exception from the requirements under Part 1271 by meeting the exception in 21 CFR 1271.15(b).

The FDA also published two final guidances intended to aid in the effort to bring innovative, safe, and effective products to patients as efficiently as possible:

Expedited Programs for Regenerative Medicine Therapies for Serious Conditions
	Evaluation of Devices Used with Regenerative Medicine Advanced TherapiesThe final guidance on expedited programs describes several programs, such as Fast Track designation and Breakthrough Therapy designation, that are available to sponsors of regenerative medicine therapies, and information about the requirements for, and benefits of, the new RMAT designation program that was created by the 21st Century Cures Act.  The final device guidance, which FDA is publishing as required by section 3034 of the 21st Century Cures Act, provides the agency’s current thinking about concepts related to the evaluation of devices used in the recovery, isolation and delivery of RMATs.

Related Information

Standards Development for Regenerative Medicine Therapies
	Guidances Related to the Regulation of Regenerative Medicine Products and Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Recording

                                                                                  Content current as of:
      05/21/2019
              
              
Regulated Product(s)
		 BiologicsCellular & Gene Therapy Products

          
                        Approved Cellular and Gene Therapy Products
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop